Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

German Drugmaker Riemser Said to Draw Private Equity Bids

May 23 (Bloomberg) -- Riemser Arzneimittel AG, one of eastern Germany’s largest drugmakers, is drawing interest from buyout firms including Warburg Pincus LLC, Montagu Private Equity LLP and Triton Advisers UK Ltd., according to people familiar with the process.

The company, based on the island of Riems, near Greifswald, may fetch as much as 300 million euros ($379 million), said the people, who declined to be identified because the talks are private. Jefferies Group Inc., which is running the sale, may select a shortlist of bidders by the end of the month, said the people.

Riemser Chief Executive Officer Michael Mehler confirmed that the drugmaker is talks with a “selected group” of private equity and strategic investors, without providing further details. He declined to comment on the timing or the price of a potential deal.

Riemser, which is owned by the Braun family, GE Healthcare Financial Services and TVM Capital, employs more than 600 people, has sales of more than 115 million euros, and exports to more than 72 countries, according to its website. It focuses on oncology, dermatology, dental products and anti-infectives.

Warburg, Montagu and Triton declined to comment.

To contact the reporters on this story: Patricia Kuo in London at; Aaron Kirchfeld in Frankfurt at; Naomi Kresge in Berlin at

To contact the editors responsible for this story: Jacqueline Simmons at; Faris Khan at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.